The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator
Primary Purpose
Osteoarthritis of the Knee
Status
Unknown status
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
Sodium hyaluronate (hyaluronic acid)
Sponsored by
About this trial
This is an interventional educational/counseling/training trial for Osteoarthritis of the Knee focused on measuring OA,HA,Intra-articular
Eligibility Criteria
Inclusion criteria:
- Patients with the diagnosis of Osteoarhtritis of the knee, graded according to Kellgren as grade 1-4
Exclusion criteria:
- Patients that suffer from acute septic arthritis.
- Patients that treated with coumadin and/or other anti-coagulant drugs
- Patients that show mental or physical conditions, which preclude compliance with study and/or device.
Sites / Locations
- Orthopedic
Outcomes
Primary Outcome Measures
To provide additional information such as the relationship between the presence of debris and symptomatic vs. asymptomatic patients.
Determining how long the injected H.A. has an effect and whether serial and periodical injections are indicated.
Secondary Outcome Measures
Full Information
NCT ID
NCT00422643
First Posted
January 15, 2007
Last Updated
January 17, 2007
Sponsor
Assaf-Harofeh Medical Center
Collaborators
Ferring Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00422643
Brief Title
The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator
Official Title
The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator
Study Type
Interventional
2. Study Status
Record Verification Date
January 2007
Overall Recruitment Status
Unknown status
Study Start Date
March 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2007 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Assaf-Harofeh Medical Center
Collaborators
Ferring Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
Osteoarthritis is the most common disease effecting human beings with incidence of about 20% and prevalence close to 80% of the adult population. It is most common after the age of 60 years and more in females with the ratio 4:1 F:M. Osteoarthritis Can be present in every hyaline joint, but is mostly damaging to the weight bearing joints, the knees and hips. At the final stage of cartilage destruction (from wear and tear) joint replacement is the solution. Since these operations were introduced about 50 years ago, the indications and the number of yearly procedures has been increasing with alarming speed. Last year in the united states, about 500,000 Total Knee procedures were done, exceeding Total Hip replacements.
By 2030, close to 4.5 million joint replacement procedures are expected in the United States, the majority of which will be knee replacements. Joint replacement is the solution for the final stage of damaged cartilage. In early and advanced stages of cartilage wear and specifically in the knee H.A. acts as an anti inflammatory and lubricant agent, reducing the knee pain and improving knee motion and function.
The biological effect of H.A. is well documented in clinical studies and less with scientific evidence derived from patients themselves.
Our study proposal briefly is, as follows:
60 patients with evidence of osteoarthritis of the knees will join the study after I.R.B. (Helsinki Committee) approval. All of them will be examined, x-rays will be performed and blood tests will exclude patients with infections or inflammatory disease. A V.A.S. (Visual Analog Score) and SF-36 evaluation form will be completed prior to each intraarticular injection, in addition to a complete medical examination. The enrolled patients will receive the usual three intraarticular knee injections of H.A.(Arthrease), but prior to each injection, the joint will be aspirated and the joint fluid will be analyzed for Chondroitin sulfate type I and type II as described further in this project.
Three and six months after the third initial injections, the patients will recalled and joint fluid will be aspirated again, followed by an H.A. injections, if symptomatic.
This study is the only one ever proposed, for evaluating joint debris qualitatively and quantitatively. It will provide clinical information as well as objective data on the preservation of the joint cartilage. Hopefully, this study will provide additional information such as the relationship between the presence of debris and symptomatic vs. asymptomatic patients. It may help in determining how long the injected H.A. has an effect and whether serial and periodical injections are indicated.
Inclusion criteria:
1. patients with the diagnosis of Osteoarhtritis of the knee, graded according to Kellgren as grade 1-4
Exclusion criteria:
Patients that suffer from acute septic arthritis.
Patients that treated with coumadin and/or other anti-coagulant drugs
Patients that show mental or physical conditions, which preclude compliance with study and/or device.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis of the Knee
Keywords
OA,HA,Intra-articular
7. Study Design
Primary Purpose
Educational/Counseling/Training
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Sodium hyaluronate (hyaluronic acid)
Primary Outcome Measure Information:
Title
To provide additional information such as the relationship between the presence of debris and symptomatic vs. asymptomatic patients.
Title
Determining how long the injected H.A. has an effect and whether serial and periodical injections are indicated.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria:
Patients with the diagnosis of Osteoarhtritis of the knee, graded according to Kellgren as grade 1-4
Exclusion criteria:
Patients that suffer from acute septic arthritis.
Patients that treated with coumadin and/or other anti-coagulant drugs
Patients that show mental or physical conditions, which preclude compliance with study and/or device.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
nahum halperin, prof
Phone
972-8-9779432
Ext
3
Email
debyroay@012.net.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ronen debi, md
Organizational Affiliation
assaf harofe medical center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Orthopedic
City
Zerifin
ZIP/Postal Code
71700
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
nahum halperin, prof
Phone
972-8-9779432
Email
debyroay@012/net.il
First Name & Middle Initial & Last Name & Degree
nahum halperin, prof
12. IPD Sharing Statement
Learn more about this trial
The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator
We'll reach out to this number within 24 hrs